Beverly Moy

13.3k total citations · 2 hit papers
214 papers, 6.1k citations indexed

About

Beverly Moy is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Beverly Moy has authored 214 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Oncology, 79 papers in Cancer Research and 70 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Beverly Moy's work include HER2/EGFR in Cancer Research (61 papers), Breast Cancer Treatment Studies (58 papers) and Advanced Breast Cancer Therapies (54 papers). Beverly Moy is often cited by papers focused on HER2/EGFR in Cancer Research (61 papers), Breast Cancer Treatment Studies (58 papers) and Advanced Breast Cancer Therapies (54 papers). Beverly Moy collaborates with scholars based in United States, Spain and France. Beverly Moy's co-authors include Paul E. Goss, Aditya Bardia, Laura M. Spring, Eric P. Winer, Steven J. Isakoff, Ann H. Partridge, Leif W. Ellisen, Hope S. Rugo, Seth A. Wander and Nicholas C. Turner and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Beverly Moy

200 papers receiving 6.0k citations

Hit Papers

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HE... 2015 2026 2018 2022 2015 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    2015 458 citations Beverly Moy, Antonio C. Wolff et al. profile →
  2. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
    2020 312 citations Laura M. Spring, Seth A. Wander et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beverly Moy United States 41 4.0k 1.8k 1.6k 804 696 214 6.1k
Debra A. Patt United States 33 4.6k 1.1× 1.3k 0.7× 1.8k 1.1× 735 0.9× 1.2k 1.7× 122 6.2k
Yu‐Ning Wong United States 36 2.1k 0.5× 1.4k 0.8× 1.7k 1.0× 377 0.5× 886 1.3× 130 5.1k
Esther Bastiaannet Netherlands 45 4.5k 1.1× 1.8k 1.0× 1.6k 1.0× 392 0.5× 847 1.2× 263 6.9k
William J. Mackillop Canada 46 2.8k 0.7× 1.0k 0.6× 2.3k 1.4× 1.3k 1.6× 567 0.8× 151 7.2k
Milena Sant Italy 37 4.5k 1.1× 1.2k 0.7× 1.6k 1.0× 418 0.5× 989 1.4× 126 8.3k
Francesco Perrone Italy 38 3.6k 0.9× 870 0.5× 1.8k 1.1× 384 0.5× 1.1k 1.6× 188 5.9k
Robert E. Bristow United States 65 2.9k 0.7× 1.3k 0.7× 1.6k 1.0× 572 0.7× 1.6k 2.3× 313 15.2k
Gerrit‐Jan Liefers Netherlands 52 5.2k 1.3× 2.8k 1.5× 1.7k 1.1× 670 0.8× 1.3k 1.9× 243 9.0k
Katherine S. Virgo United States 50 4.7k 1.2× 1.0k 0.6× 3.1k 1.9× 823 1.0× 1.1k 1.5× 203 10.9k
Karen E. Hoffman United States 35 1.9k 0.5× 1.3k 0.7× 1.1k 0.7× 650 0.8× 335 0.5× 107 4.7k

Countries citing papers authored by Beverly Moy

Since Specialization
Citations

This map shows the geographic impact of Beverly Moy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beverly Moy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beverly Moy more than expected).

Fields of papers citing papers by Beverly Moy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beverly Moy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beverly Moy. The network helps show where Beverly Moy may publish in the future.

Co-authorship network of co-authors of Beverly Moy

This figure shows the co-authorship network connecting the top 25 collaborators of Beverly Moy. A scholar is included among the top collaborators of Beverly Moy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beverly Moy. Beverly Moy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Medford, Arielle J. & Beverly Moy. (2024). Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations. JCO Oncology Practice. 20(11). 1515–1522. 2 indexed citations
2.
Perez, Giselle K., et al.. (2023). Qualitative study of Oncology Clinicians’ Perceptions of Barriers to Offering Clinical Trials to Underserved Populations. Cancer Control. 30. 2915605877–2915605877. 5 indexed citations
3.
4.
Medford, Arielle J., et al.. (2023). Circulating Tumor DNA in Breast Cancer: Current and Future Applications. Clinical Breast Cancer. 23(7). 687–692. 7 indexed citations
5.
Medford, Arielle J., Lauren Oshry, Bariş Boyraz, et al.. (2023). TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Therapeutic Advances in Medical Oncology. 15. 2597580–2597580. 5 indexed citations
6.
7.
Hantel, Andrew, Rebecca Spence, Angela R. Bradbury, et al.. (2023). ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages. Journal of Clinical Oncology. 42(3). 358–365. 5 indexed citations
8.
Medford, Arielle J., Beverly Moy, Laura M. Spring, et al.. (2023). Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clinical Cancer Research. 29(22). 4540–4548. 25 indexed citations
9.
Perni, Subha, et al.. (2022). Financial Toxicity, Symptom Burden, Illness Perceptions, and Communication Confidence in Cancer Clinical Trial Participants. JCO Oncology Practice. 18(9). e1427–e1437. 15 indexed citations
10.
Vidula, Neelima, Andrzej Niemierko, Jochen K. Lennerz, et al.. (2021). Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3404–3413. 12 indexed citations
11.
Saura, Cristina, Judit Matito, Mafalda Oliveira, et al.. (2021). Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research. 27(21). 5818–5827. 15 indexed citations
12.
Medford, Arielle J., Laura M. Spring, Beverly Moy, & Aditya Bardia. (2021). Antibody drug conjugates for patients with breast cancer. Current Problems in Cancer. 45(5). 100795–100795. 3 indexed citations
13.
Smith, Barbara L., Bridget N. Kelly, Michelle C. Specht, et al.. (2020). A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. Breast Cancer Research and Treatment. 183(3). 515–524. 13 indexed citations
14.
Juric, Dejan, Andrzej Niemierko, Laura M. Spring, et al.. (2020). Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology. 1246–1262. 15 indexed citations
15.
Drago, Joshua Z., Luigi Formisano, Dejan Juric, et al.. (2019). FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer. Clinical Cancer Research. 25(21). 6443–6451. 47 indexed citations
16.
Sepucha, Karen, Aisha T. Langford, Jeffrey Belkora, et al.. (2019). Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. Medical Decision Making. 39(6). 642–650. 12 indexed citations
17.
Keenan, Tanya E., Beverly Moy, Edmund A. Mroz, et al.. (2015). Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. Journal of Clinical Oncology. 33(31). 3621–3627. 168 indexed citations
18.
Jacobson, Brian C., Beverly Moy, Graham A. Colditz, & Charles S. Fuchs. (2009). Postmenopausal Hormone Use and Symptoms of Gastroesophageal Reflux. Obstetrical & Gynecological Survey. 64(3). 172–174. 5 indexed citations
19.
20.
Moy, Beverly, Peter Kirkpatrick, Santwana Kar, & Paul E. Goss. (2007). Lapatinib. Nature Reviews Drug Discovery. 6(6). 431–432. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Debra A. Patt Breakdown of academic impact, for papers by Yu‐Ning Wong Breakdown of academic impact, for papers by Esther Bastiaannet Breakdown of academic impact, for papers by William J. Mackillop Breakdown of academic impact, for papers by Milena Sant Breakdown of academic impact, for papers by Francesco Perrone Breakdown of academic impact, for papers by Robert E. Bristow Breakdown of academic impact, for papers by Gerrit‐Jan Liefers Breakdown of academic impact, for papers by Katherine S. Virgo Breakdown of academic impact, for papers by Karen E. Hoffman
Rankless by CCL
2026